Full Breakdown
Cytokinetics Secures FDA Approval for Myqorzo, a New Treatment for Obstructive Hypertrophic Cardiomyopathy
12/20/2025, 8:18:05 PM
FDA Approval and Drug Overview
On December 19, 2025, the U.S. Food and Drug Administration (FDA) approved Cytokinetics' new drug, Myqorzo (chemical name: aficamten), for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). This condition, characterized by an abnormal thickening of the heart muscle, affects approximately one in every 500 people in the United States, leading to symptoms such as shortness of breath, chest pain, and dizziness. Myqorzo is notable as it is Cytokinetics' first FDA-approved product and only the second drug in its class to receive U.S. clearance, following Bristol Myers Squibb's (BMY) Camzyos, which was approved in 2022.
Mechanism and Clinical Trials
Myqorzo functions as a cardiac myosin inhibitor, designed to reduce the forceful contractions of the heart muscle. In clinical trials, aficamten demonstrated superior efficacy compared to the standard treatment, metoprolol, improving exercise capacity and alleviating symptoms in patients with oHCM. The drug is expected to be available in the U.S. by late January 2026, although it will carry a serious warning regarding the risk of heart failure and will be distributed under a risk evaluation and mitigation strategy (REMS).
Competitive Landscape
Cytokinetics is entering a competitive market, as Camzyos has already established a significant presence, generating over $1 billion in annual sales. Analysts suggest that Myqorzo could potentially capture a substantial share of the oHCM market, with estimates of peak sales reaching up to $4 billion, and possibly $10 billion if it successfully expands into non-obstructive HCM (nHCM) as well. Cytokinetics has already initiated a Phase III trial for aficamten in nHCM, following promising results from earlier studies.
Official Statements & Responses
Cytokinetics CEO Robert Blum emphasized the company's long-term strategy, stating, “Twenty-seven years ago, we embarked on this journey of developing inhibitors of cardiac disease. Commercialization has been our plan since day one.” He also noted that the company aims to market aficamten independently in the U.S. and Europe, while considering partnerships for commercialization in other regions.
Criticism & Opposition
Despite the optimism surrounding Myqorzo, some analysts express caution regarding its market potential. Truist analysts project a more conservative peak revenue of $3.4 billion for aficamten in oHCM, along with an additional $460 million for nHCM. This disparity in revenue forecasts highlights the uncertainty surrounding the drug's market performance against established competitors.
Conflicting Reports & Gaps
While Cytokinetics anticipates significant revenue from Myqorzo, there are differing opinions on its market impact. Some analysts predict a robust performance, while others remain skeptical about its ability to compete effectively against Camzyos. Additionally, the exact pricing for Myqorzo has not yet been disclosed, which may influence its market acceptance.
Verbatim Quotes
- “Twenty-seven years ago, we embarked on this journey of developing inhibitors of cardiac disease,” — Robert Blum, CEO of Cytokinetics
- “We think [Cytokinetics] has a very credible chance to be the only drug available for the entire HCM spectrum,” — Stifel Analysts
Cytokinetics' approval of Myqorzo marks a significant milestone in the treatment of oHCM, with potential implications for both patient care and the company's future in the pharmaceutical market.
